The chief executive of pharmaceutical company Élan, Kelly Martin, has said he is very confident that its suspended Multiple Sclerosis drug, Tysabri, will find a pathway back to the market.
Speaking at the firm's annual general meeting in Dublin, Mr Martin also revealed that the company is continuing to manufacture the drug.
He said the take-up had been 'extraordinary' when it had been on the market and Élan did not want the drug to be unavailable at any stage.
The drug was withdrawn from the market in February, wiping 70% off the value of the company.
It was withdrawn after it was discovered two patients treated with the drug developed a brain disease known as PML. One of the patients died.